Young Scholars’ Developments in Immunology

A special issue of Immuno (ISSN 2673-5601).

Deadline for manuscript submissions: 28 February 2026 | Viewed by 293

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pathology, Sapporo Medical University School of Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan
Interests: onco-immunology; cancer immunotherapy; immunopathology; CAR-T cell; tumor microenvironment; cancer vaccine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biotechnology, The Arab American University (Jenin), PA and Al-Qasemi Academic College, Baga Algharbiya, Israel
Interests: anti-inflammatory; immunomodulatory medicinal plants; in vitro biological assessment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Once overlooked and poorly understood, inflammation is now everywhere we look—from the root of chronic disease to the focus of cutting-edge therapies. Whether in a lab, a clinic, or a television commercial, we are constantly hearing about the immune system—how to fine-tune it, how to calm it, or how it goes wrong. Today, almost every major disease is tied to dysregulated immune and inflammatory signaling.

This Special Issue of Immuno, “Young Scholars’ Developments in Immunology”, celebrates the discoveries of early-career researchers shaping the future of immunological sciences. We invite original research articles and reviews from PhD students, postdoctoral fellows, and new principal investigators across the full spectrum of immunology.

We particularly encourage contributions focused on innate immune mechanisms, including inflammatory signaling, cytokine networks, pattern recognition, protease activity, and programmed cell death pathways, such as apoptosis, pyroptosis, and necroptosis. However, we also welcome studies exploring the interface of innate and adaptive immunity, immune cell differentiation, host–pathogen interactions, and immune dysregulation in infection, cancer, and autoimmunity.

This Issue aims to act as a space to spotlight bold ideas, novel tools, and fresh perspectives from the next generation of immunologists. Join us in sharing the science that will shape tomorrow’s immune therapies and discoveries.

Prof. Dr. Toshihiko Torigoe
Prof. Dr. Bashar Saad
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation
  • innate immunity
  • adaptive immunity
  • cell death
  • cytokines/cytokine signaling
  • host–pathogen interactions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 1727 KB  
Article
Immunomodulatory Effects of Epilobium Angustifolium Extract in DSS-Induced Colitis: Attenuation of Inflammatory and Metabolic Markers in Mice
by Rositsa Mihaylova, Viktoria Elincheva, Reneta Gevrenova, Dimitrina Zheleva-Dimitrova, Georgi Momekov and Rumyana Simeonova
Immuno 2025, 5(4), 50; https://doi.org/10.3390/immuno5040050 - 19 Oct 2025
Abstract
The inflammatory and metabolic complexity of colitis necessitates therapies that act on multiple immune pathways. Using serum proteomic profiling, the present study evaluated the systemic immunomodulatory profile of Epilobium angustifolium lyophilized methanol-aqueous extract rich in oenothein B (EAE) in a dextran sulfate sodium [...] Read more.
The inflammatory and metabolic complexity of colitis necessitates therapies that act on multiple immune pathways. Using serum proteomic profiling, the present study evaluated the systemic immunomodulatory profile of Epilobium angustifolium lyophilized methanol-aqueous extract rich in oenothein B (EAE) in a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis in a comparative manner to dexamethasone (DXM). DSS exposure triggered robust inflammatory activation, evidenced by elevated chemokines (CXCL9, CXCL10, CCL11), proinflammatory cytokines (IL-1α, IL-12, PAI-1, RAGE) and metabolic stress mediators (leptin, resistin, FGF-21). Treatment with EAE significantly attenuated this inflammatory profile, notably reducing Th2-skewed chemokines and eosinophil recruitment. In contrast to DXM, EAE uniquely normalized pro-thrombotic and tissue-remodeling markers, including PAI-1 and RAGE, both implicated in intestinal barrier dysfunction and chronic inflammation. Furthermore, EAE demonstrated superior modulation of inflammation-associated growth factors (IGFBP-5, HGF, Flt3L) and adipokines (leptin, resistin), indicating a broader therapeutic scope that includes metabolic dysfunctions. Collectively, our data reveal that EAE exerts a distinct immunoregulatory profile, modulating both innate and adaptive immune pathways while simultaneously addressing metabolic pathologies. These multifaceted actions underscore its promise as a phytotherapeutic candidate for the management of ulcerative colitis and other inflammatory conditions, with potential advantages over conventional steroid treatment. Full article
(This article belongs to the Special Issue Young Scholars’ Developments in Immunology)
Back to TopTop